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Topotecan (Hycamtin), a semisynthetic water-soluble derivate of
camptothecin, is a potent inhibitor of DNA topoisomerase I in
vitro (Kingsbury et al, 1991) and has demonstrated promising anti-
tumour activity in a wide variety of tumours, including ovarian
cancer and small cell lung cancer (Ten Bokkel Huinink et al, 1997;
Ardizzonni et al, 1997). A recent study showed that topotecan has
efficacy at least equivalent to paclitaxel manifested by a higher
response rate and longer time to progression in patients with recur-
rent epithelial ovarian cancer and it has shown cytotoxic activity in
patients refractory to platinum and paclitaxel (Ten Bokkel Huinink
et al, 1997). In patients who failed platinum based chemotherapy,
response rates ranged from 13% to 25% with a duration of 22–32
weeks (Neijt et al, 1991; Kudelka et al, 1996; Ten Bokkel Huinink
et al, 1997). Topotecan binds with the topoisomerase I-DNA
complex and interferes with the process of DNA breakage and
resealing, resulting in DNA breaks, fragmentation and cell death
(Hertzberg et al, 1989; Hsiang et al, 1989). To date, activity has been
observed primarily with continuous and frequent dosing schedules,
particularly when topotecan is given as a 1.5 mg/m2/day infusion on
5 consecutive days every 21 days, with myelotoxicity as the dose
limiting factor (Kudelka et al, 1996; Ten Bokkel Huinink et al,
1997). Under physiological conditions the active lactone moiety of
topotecan undergoes a rapid and reversible pH-dependent conver-
sion into a carboxylated open-ring form, with less topoisomerase I
inhibiting activity. At pH 7.4 the open-ring form predominates at
equilibrium and topotecan is stable in infusion fluids at pH < 4.0,
but unstable in plasma (Rowinsky et al, 1992; Verweij et al, 1993;
Herben et al, 1996). 
Direct intraperitoneal (IP) installation of some cytotoxic agents
offers the potential of exposing the IP tumour to high concentra-
tions with less of the usual systemic side effects (Markman et al,
1992; Markman, 1998a). Randomized studies have shown less
toxicity and an increased disease free survival in the group treated
with IP chemotherapy (Alberts et al, 1996; Markman et al, 1998b;
Hofstra et al, 2000). A study on the feasibility of a triple drug
schedule with cisplatin, paclitaxel and topotecan has shown that
full IV doses of these drugs can not be reached due to severe
myelotoxicity (Herben et al, 1999). We wanted to study if IP instil-
lation of full doses of topotecan would be possible without pro-
hibitive myelotoxicity, with the aim to combine this drug with
standard doses of the two other compounds in a subsequent study.
Therefore, the aim of this study was to investigate the safety and
pharmacokinetic properties of IP topotecan in patients with recur-
rent ovarian cancer. 
PATIENTS AND METHODS 
Patients 
Eligible patients were between 18 and 75 years of age with
advanced recurrent ovarian cancer and with a life expectancy of
> 12 weeks. In the absence of histological evidence of disease
progression, patients could be entered into this trial on the basis of
repeated elevated CA125 levels. Patients had received at least
one prior treatment with platinum- and paclitaxel containing
chemotherapy, but no topotecan or other topo-isomerase inhibitors.
All patients had a performance status of 0–2, according to WHO
criteria, normal blood counts (leucocytes 3.0 × 109/L, platelets 100
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limit) or liver function (bilirubin 1.5 × upper normal limit).
Exclusion criteria included patients with borderline ovarian
tumours or germ cell tumours, complete bowel obstruction, a
history of atrial or ventricular arrhythmias, congestive heart
failure, or documented myocardial infarction within the previous 6
months. Patients with active infection or other serious medical
conditions were also excluded. Finally, patients with peritoneal
adhesions which preclude homogenous distribution of peritoneal
fluid were excluded. The study was approved by the local Ethical
Committee. All patients gave written informed consent. 
Treatment plan 
All patients had a surgically implanted peritoneal-access-port
(PAP) catheter (Arts et al, 1998). Before administration of IP
topotecan, fluid distribution was controlled by the instillation of
99Tc-colloid and an even distribution over all four quadrants was
obligatory for study entry. (Levenback et al, 1994). Formulated
topotecan, dissolved in 1 L of normal saline (pH = 4) was infused
over 1 h into the abdominal cavity, after previous infusion of 1 L
of normal saline at 37˚C on day 1. The projected dose steps of
topotecan were 5–10–15–20–30 mg/m2/day IP in 3 patients on
each dose level. 
Cycles were repeated every 3 weeks to a maximum of 8.
Ondansetron 8 mg was administered IV 1 h prior to topotecan
infusion. Standard slow-release morphine 20 mg orally and rectal
diazepam 10 mg were administered once before topotecan infu-
sion in order to minimize acute abdominal discomfort to keep the
patient comfortable during the period of IP infusion. No steroids
were given before or after topotecan. In case of inadequate bone
marrow recovery on day 21 (leucocytes <3.0 × 109/L or platelets
<100 × 109), administration was delayed for 1 week. Patients went
off study in case of tumour progression, topotecan hypersensi-
tivity, or after completing 8 treatment cycles. Non-haematologic
toxicity grade III or higher, infection or bleeding due to haemato-
logic toxicity or haematological toxicity grade IV led to dose
reduction to the nearest level and repeated haematological toxicity
grade IV to discontinuation of treatment. For the determination of
dose-limiting toxicity and the MTD, grade IV haematologic and
grade III non-haematologic toxicity were considered as dose-
limiting for this study. 
Assessment 
At baseline and before each cycle of therapy, a physical examina-
tion was performed, with a complete blood count, serum CA125
(IMX Ca-125, Abbott Diagnostics, Chicago, IL) and blood chem-
ical measurements. On day 8 and 15 of each cycle a complete
blood count was performed. All initially positive radiology (CT-
scan, ultrasound) examinations were repeated after completion of
therapy. Toxicities were recorded according to the WHO grading
system. A complete response was defined as no clinical evidence
of disease including a normalized CA125 level. 
METHODS 
Topotecan pharmacokinetics 
Pharmacokinetic sampling was performed on day 1 of the first
treatment cycle. Serum and IP fluid samples were collected at 0, 1,
2, 4, 6, 10 and 24 h after the start of IP topotecan, which was admin-
istered at 37˚C over 1 h. Plasma was withdrawn by IV sampling and
IP-fluid via the PAP-catheter and both were collected in heparinized
tubes on ice. Before the collection of each IP sample, 2 mL of peri-
toneal fluid was discarded for potential topotecan-residue in the
catheter (internal volume about 0.5 mL). All samples were centri-
fuged immediately after sampling at 3000 g for 5 min at 4˚C. To
prevent conversion of the lactone form to the open form, a volume
of 1.0 ml methanol at –20˚C was added to 0.5 mL of the separated
plasma. The sample was then centrifuged for 5 min and the super-
natant was transferred to a clean tube. All samples were stored at
–80˚C until analysis. Plasma and peritoneal fluid levels of topo-
tecan were determined using a validated high-performance liquid
chromatography (HPLC) method with UV detection as previously
reported (Rosing et al, 1995; Herben, 1996). The plasma concen-
tration curves were fitted by using the Kinfit computer program
(MW\Pharm, Medi\Ware BV, Groningen, The Netherlands)
(Proost and Meijer, 1992). Kinetic parameters were calculated
using standard equations. The total Area Under the Concentration-
time curve (AUC), was calculated by the linear trapezoidal
method. For the calculation of the other parameters however, the
fitted AUC curve according to the computed exponential model
was applied. 
RESULTS 
Patient characteristics are summarized in Table 1. A total of 75
cycles of IP topotecan were administered to 15 patients enrolled in
the study. Dose steps and dose limiting haematologic toxicity
are displayed in Table 2. In one patient at 15 mg/m2 and one at 30
mg/m2 the dose level was reduced for toxicity as described below. 
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Table 1 Patient characteristics (n = 15) 
Number of patients 15 
Age (years) 
median 55 
range 41–68 
WHO Performance status 
09  
15  
21  
Prior chemotherapy regimens 
IP paclitaxel with IV carboplatin/cyclophosphamide 15 
Second line treatment with 
Oral etoposide 2 
Oral L-PAM 2 
Table 2 Topotecan dose level, number of cycles and worst haematologic
toxicity per dose level 
Toxicity 
opotecan  No. of No. of
IP dose  patients cycles WBC (109/L) Platelets (109/L)
(mg/m2)
Grade III Grade IV Grade III Grade IV 
53 1 0 0 0 0 0  
10 3 13 0 0 0 0 
15 3 21 1 1 1 0 
20 3 22 2 0 1 0 
30 3 8 2 0 0 0 
Total 15 74 5 1 2 0 Only mild to moderate (grade I-III) haematological toxicity was
encountered starting from the 15 mg/m2 dose level. At 15 mg/m2
one patient experienced a grade IV leukopenia and grade III
thrombocytopenia during the first treatment cycle; subsequent
treatment with 10 mg/m2 did not give further myelosuppression.
Four of the six patients treated at higher doses had grade III
leukopenia and one patient had a grade III thrombocytopenia
(Table 2). The duration of myelosuppression was short (< 7 days)
and non-cumulative and haematological toxicity resulted in dose
reduction in two patients but no delay of the next cycle. One
admission on day 9–11 for grade IV neutropenic fever was record-
ed at the 30 mg/m2 dose level. No bleeding episodes occurred. 
Non-haematological toxicity 
Dose limiting toxicity (DLT) was encountered at the 30 mg/m2
dose level (Table 3). DLT was an acute reaction in one patient
immediately after infusion of the full dose of topotecan comprising
severe hypotension, fever (39.7˚C) and chills without an infectious
focus. Rapid treatment with volume expanders and IV antihista-
mines resulted in a full recovery within hours without sequelae.
This patient continued with IV topotecan 1.5 mg/m2/day over 5
days every 21 days without further problems. She had had no prior
exposure to topo-I inhibitors, and had previously been treated with
IP paclitaxel without local problems. 
Nausea and/or vomiting grade I-II was recorded in 12 patients.
Nausea and vomiting was grade III in three patients at the two
highest dose levels. Patients responded to standard anti-emetics
and this did not result in prolonged hospitalization. 
Abdominal pain grade I was observed in six patients and was
not related to the topotecan dose level. All patients treated with
topotecan 15 mg/m2 or more developed alopecia grade II. A gener-
alized but transient skin rash was observed in four patients starting
3–5 days following IP administration. In one of these four patients,
treated at 15 mg/m2, for a rash combined with fever and grade IV
leukopenia and grade III thrombocytopenia the dose was reduced
to 10 mg/m2. Re-treatment with topotecan did not result in a reap-
pearance of skin rashes in one of these patients. Two of the three
patients treated at 30 mg/m2 dose level complained of grade II
headache, which responded to acetaminophen and did not need
dose-reduction or prolonged hospitalization. 
Tumour responses 
In these pretreated patients no complete clinical responses were
observed. Seven patients had no clinical parameter and two had no
detectable marker. Partial responses, defined by a > 50% decrease
in repeated CA125 levels were observed in 6 of 13 biochemically
evaluable patients. Stable disease for 6–8 cycles was observed in 5
of 8 clinically evaluable patients. Progressive disease, defined by
the appearance of new lesions or an increase by > 50% in tumour
measurements or in repeated CA125 levels was observed in six
patients, three by marker and three by clinical parameters. The
duration of treatment was not different for the dose levels
studied. 
Topotecan IP pharmacokinetics 
Peritoneal samples for pharmacokinetic analysis were available
from seven patients. In the other patients, collection of peritoneal
fluid from the PAP-catheter was impossible due to pericatheter
fibrosis, leading to backflow valve formation and absent backflow.
The intraperitoneal pharmacokinetic parameters of total topotecan
are presented in Table 5A and B. The elimination phase of total
topotecan (lactone plus carboxy forms) from the peritoneal cavity
was best described by a mono-exponential model. The mean T1/2
for the peritoneal compartment was 2.7 ± 1.7 h. The AUC of total
topotecan in peritoneal fluid was proportional with dose, as shown
in Figure 1, R = 0.84, P < 0.01 The peritoneal to plasma AUC ratio
for total topotecan was 54 ± 34. The IP lactone showed a shorter
half-life of 2.3 ± 2.0 h, probably due to intraperitoneal conversion,
as the lactone is unstable in a neutral pH within the abdominal
cavity. As a consequence, the peritoneal lactone/total topotecan
AUC ratio was 15–52%, median 29%. 
Topotecan plasma pharmacokinetics 
The plasma kinetics of topotecan of 13 patients were best
described by a one compartmental model. The plasma pharmaco-
kinetic parameters of total topotecan and of lactone are presented
in Table 4A and B. The plasma peak levels (Cmax) of total
topotecan were reached at 2.7 ± 1.1 h and of lactone 2.1 ± 0.6 h
after the start of IP administration and were dose-dependent (resp.
R = 0.92 and R = 0.92, for both P < 0.01). The mean T1/2 was 3.7
± 1.3 h for total topotecan and 5.2 ± 2.2 h for lactone. The mean
AUC, which represents the total plasma exposure time, was
proportional with dose, R = 0.95, P < 0.01 for total topotecan
Topotecan IP in ovarian cancer 1629
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Table 3 Topotecan dose level, number of cycles and worst 
non-haematologic toxicity per dose level 
Dose (mg/m2) 5 10 15 20 30 
Number of  Toxicity 
patients WHO Grade 3 3 3 3 3 
Nausea II 1 2 3 1 1 
III 0 0 0 2 1 
Emesis II 0 0 2 1 1 
III 0 0 0 2 1 
Rash II 0 0 1 0 0 
III 0 0 0 1 1 
Fatigue II 0 0 0 2 1 
III 0 0 0 1 1 
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Figure 1 AUC of peritoneal total topotecan versus dose administered in
mg.h/L for individual patients, R = 0.841630 LS Hofstra et al
British Journal of Cancer (2001) 85(11), 1627–1633 © 2001 Cancer Research Campaign
Table 4A Plasma pharmacokinetics of total topotecan 
Patient Dose  Absolute Body AUC CL Vss T1/2 MRT kel Tmax Cmax
no. (mg/m2) dose surface 0  →  ∞ (L/h/m2)( L / m 2) (h) (h) (x/h) (h) (µ g/L)
(mg) (m2) (h/µ g/L)
1 5 8 1.80 181 17.6 20.8 0.8 3.6 0.85 2.1 61.8 
2 5 8 1.62 380 14.0 87.7 4.3 8.5 0.16 3.6 33.8 
3 10 16 1.60 684 15.8 77.6 3.4 6.6 0.20 2.7 80.2 
4 10 16 1.60 690 16.1 74.3 3.2 6.8 0.22 3.2 79.4 
5 15 28 1.78 1153 13.9 114.6 5.7 11.9 0.12 5.4 75.3 
6 15 28 1.80 1406 13.5 95.1 4.9 8.0 0.14 1.2 153.7 
7 15 28 1.80 1910 9.1 49.4 3.8 6.5 0.18 1.4 289.4 
8 20 35 1.75 1566 14.2 66.1 3.2 7.0 0.21 3.3 178.5 
9 20 43 2.16 1434 12.7 85.6 4.7 8.1 0.15 2.6 169.3 
10 20 36 1.80 2036 11.0 30.9 1.9 6.9 0.36 3.5 202.9 
11 30 66 2.22 2322 14.7 74.2 3.5 6.0 0.20 1.9 297.2 
12 30 52 1.75 2539 12.6 62.0 3.4 6.0 0.20 2.1 341.1 
13 30 53 1.70 3784 9.6 70.7 5.1 8.6 0.14 2.4 331.8 
Mean 13.4 69.9 3.7 7.3 0.24 2.7 
SD 2.5 25.4 1.3 1.9 0.19 1.1 
Table 4B Plasma pharmacokinetics of lactone 
Patient Dose Absolute Body AUC CL Vss T1/2 MRT kel Tmax Cmax
no. (mg/m2) dose surface 0 →  ∞ (L/h/m2)( L / m 2) (h) (h) (x/h) (h) (µ g/L)
(mg) (m2) (h/µ g/L)
1 5 8 1.80 81 52.1 348 4.6 7.0 0.15 1.1 11.0 
2 5 8 1.62 66 78.6 664 5.9 9.7 0.12 2.8 5.3 
3 10 16 1.60 107 98.1 556 3.9 6.5 0.18 1.7 14.0 
4 10 16 1.60 131 83.1 452 3.7 7.0 0.18 2.6 15.3 
5 15 28 1.78 185 81.8 1366 11.6 17.7 0.06 1.6 11.1 
6 15 28 1.80 489 45.1 365 5.6 9.6 0.12 2.4 35.8 
7 15 28 1.80 618 31.2 156 3.5 6.4 0.20 2.5 61.0 
8 20 35 1.75 323 66.0 422 4.4 8.1 0.16 3.0 32.9 
9 20 43 2.16 652 28.7 212 5.1 8.6 0.14 2.3 73.2 
10 20 36 1.80 499 52.9 273 3.6 6.5 0.19 2.5 45.6 
11 30 66 2.22 1267 28.4 156 3.8 6.4 0.18 1.8 144.9 
12 30 52 1.75 1104 27.8 172 4.3 6.9 0.16 1.5 145.6 
13 30 53 1.70 1286 24.2 265 7.6 11.9 0.09 2.2 97.7 
Mean 53.7 416 5.2 8.6 0.15 2.1 
SD 25.5 326 2.2 3.2 0.04 0.6 
Table 5A Intraperitoneal pharmacokinetics of total topotecan (Please note the difference × 1000 in units, mg versus µ g as in Table 4A and B) 
Patient Dose Absolute Body AUC CL Vss T1/2 MRT kel Cmax
no. (mg/m2) dose surface 0 →  ∞ (L/h/m2)( L / m 2) (h) (h) (x/h) (mg/L) 
(mg) (m2) (h/mg/L)
3 10 16 1.60 30 0.3 1.3 1.8 2.6 0.38 5.72 
5 15 28 1.78 76 0.2 3.7 6.6 9.5 0.11 8.93 
6 15 28 1.80 23 0.9 4.1 1.8 2.6 0.38 9.11 
7 15 28 1.80 20 0.9 4.4 1.8 2.6 0.39 7.36 
8 20 35 1.75 162 0.2 0.9 2.3 3.3 0.30 36.15 
9 20 43 2.16 121 0.4 2.7 2.2 3.2 0.31 11.30 
11 30 66 2.22 133 0.3 2.0 2.3 3.4 0.30 34.40 
Mean 0.4 2.7 2.7 3.9 0.31 
SD 0.3 1.4 1.7 2.5 0.10 
Table 5B Intraperitoneal pharmacokinetics of lactone (Please note the difference × 1000 in units, µ g versus mg in Table 4A and B) 
Patient Dose Absolute Body AUC CL Vss T1/2 MRT kel Cmax
no. (mg/m2) dose surface 0 →  ∞ (L/h/m2)( L / m 2) (h) (h) (x/h) (mg/L) 
(mg) (m2) (h/mg/L)
8 20 35 1.75 85 0.2 2.8 4.6 6.7 0.15 12.1 
9 20 43 2.16 18 1.2 3.6 1.0 1.4 0.71 10.5 
11 30 66 2.22 39 1.0 4.2 1.3 1.8 0.55 21.5 
Mean 0.8 3.5 2.3 3.3 0.47 
SD 0.5 0.7 2.0 2.9 0.29 (Figure 2) and R = 0.91 P < 0.01 for lactone (Figure 3). The mean
plasma clearance of total topotecan was 13.4 ± 2.5 L/h/m2 with a
mean volume of distribution (Vss) of 69.9 ± 25.4 L/m2. The mean
plasma clearance of lactone was 53.7 ± 25.5 L/h/m2 with a mean
volume of distribution (Vss) of 416 ± 326 L/m2. It might be better
to speak of ‘apparent’ plasma clearance (CI/F) and volume of
distribution (Vss/F), as the exact fraction (of the total amount of
active lactone administered IP) which reaches the plasma 
compartment is not known. The AUC ratio between lactone and
total topotecan in plasma is shown in Figure 4, illustrating a
proportional relationship with the dose, R = 0.84, P < 0.01. 
Figure 5 shows the peritoneal and plasma concentration versus
time curve of total topotecan and lactone for one representative
patient at 30 mg/m2, indicating that peritoneal concentrations are
about 100 times higher than plasma levels and that plasma
topotecan levels were sustained during several hours above a
threshold concentration of 100 µ g/L, which is reported as an active
concentration in vitro (Burris et al, 1992). 
DISCUSSION 
The activity of single-agent topotecan in refractory ovarian cancer,
and the fact that IP instillation can avoid myelotoxicity, served as
the rationale for this study (Markman et al, 1992; Ten Bokkel
Huinink et al, 1997). Clinical and pharmacological data of intra-
peritoneal topotecan administration are sparse (Pratesi et al, 1995;
Plaxe et al, 1998) and topotecan efficacy and pharmacokinetics is
mostly studied during IV schedules (Herben et al, 1996; Hoskins
et al, 1998). The recommended cumulative dose of topotecan in
these studies lies between 4 and 22.5 mg/m2: 4 mg/m2 as 24-h
continuous IP infusion (Plaxe et al, 1998), 7.5 mg/m2 as daily × 5
bolus IV (Ten Bokkel Huinink et al, 1997), 8–10 mg/m2 as a 24-h
continuous IV infusion (Abbruzzese et al, 1993; Van Warmerdam
et al, 1995), 10.5 mg/m2 as a continuous 5-day infusion
(Kantarjian et al, 1993; Rowinsky et al, 1994) or 12.6–16.8 mg/m2
as a continuous 21-day IV infusion (Hochster et al, 1995) and
17.5–22.5 mg/m2 as daily × 5 IV bolus combined with G-CSF
(Rowinsky et al, 1992; Wall et al, 1992; Rowinsky et al, 1996).
Repeated exposure seems to be more active, as in the clinic a 5-day
schedule has been proven to be more effective than a continuous
infusion over 24 h (Hoskins et al, 1998), in a so-called ‘pick the
winner’ comparative phase II study design. 
The acute and severely toxic event in the third patient on a
dose of 30 mg/m2 was considered to be dose-limiting and a dose
of 20 mg/m2 topotecan was thought to constitute the maximum
tolerated dose (MTD) of topotecan. However, up to this point
other WHO grade haematological and non-haematological toxicity
was considered acceptable. If this acute toxic event in one
Topotecan IP in ovarian cancer 1631
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Figure 2 AUC of plasma total topotecan versus dose administered in
µ g.h/L for individual patients, R = 0.95. Please note the difference in units
(:1000) versus the peritoneal drug levels in Figure 1
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Figure 3 AUC of plasma lactone topotecan versus dose administered in
µ g.h/L for individual patients, R = 0.91. Please note the difference in units
(:1000) versus the peritoneal drug levels in Figure 1
Figure 4 Ratio between plasma AUC of lactone and total topotecan for
individual patients, R = 0.84
Figure 5 Plasma and IP concentration of lactone and total topotecan in
peritoneal fluid and plasma in a representative patient after 30 mg/m2
topotecan IP. The squares represent lactone, the circles total topotecan;
open symbols are peritoneal samples, closed symbols are plasma samples.
The interrupted line represents a minimal inhibitory topotecan concentration
in vitro of 100 µ g/Lpatient would be considered as a random phenomenon, even a dose
of 30 mg/m2 might be acceptable, as it was well-tolerated otherwise. 
In vitro, cytotoxic activity of topotecan has been demonstrated
for continuous exposure above a threshold concentration of 100
µ g/L (Burris et al, 1992). Other studies mention cytotoxic concen-
trations of 5.5 µ g/L (Mi et al, 1995), 13.7–229 µ g/L (Pizao et al,
1994) and 128 µ g/L (Tanizawa et al, 1994), depending on the
methods used in the assay. In this study, plasma topotecan concen-
trations required for cytotoxicity in vitro were reached from the 15
mg/m2 dose level onwards. In the peritoneal samples, a limit of
100 µ g/L is exceeded by a Cmax of 5000 = a factor 50 at the 10
mg/m2 dose level. 
Another observation in this study is that the lactone/total
topotecan ratio increases and becomes more favourable at the
higher dose levels. As the lactone form is mainly responsible for
the cytotoxic effects of topotecan, this implies that at higher dose
levels there is not only an absolute but also a relative increase in
active topotecan; however, the therapeutic relevance of this
finding remains to be established. 
The pharmacokinetic data we found after IP administration is in
good agreement with the data of others. During continuous IP
infusion, Plaxe et al found a terminal T1/2 for peritoneal topotecan
of 2.7 ± 0.4 h and for plasma total topotecan a T1/2 of 3.9 ± 2.1 h
(Plaxe et al, 1998), which is similar to our data. After IV adminis-
tration of much lower doses (1.5 mg/m2 bolus), Herben et al
reported similar T1/2 for total topotecan, but shorter T1/2 values
for the lactone, 2.1 vs 5.5 hours in this study (Rowinsky et al,
1992; Verweij et al, 1993). This can probably be explained
because there is a steady flow of lactone from the peritoneal cavity
into the plasma compartment, keeping the lactone concentration
up, in spite of its simultaneous conversion within the plasma to the
less active carboxy compound. As a consequence thereof, Herben
et al reported a Vss of 94 L/m2 for lactone, while we found 416
L/m2 for these higher dosages. Therefore, for plasma kinetics, we
should probably use the terms ‘apparent clearance’ (CI/F) and
volume of distribution (Vss/F), as the exact fraction of the total
amount of active lactone administered, which contributes to the
concentration of total topotecan and lactone in the plasma, is
presently unknown. 
The data are in good agreement with those of other studies
(Herben et al, 1999; Abbruzzese et al, 1993). In view of a plasma
T1/2 for total topotecan of about 2 h, after 12 h the concentration of
total topotecan would lie around 1.5% of the initial concentration
(6 × T1/2). The concentration/ time curves found after 12 hours will
then be mainly determined by influx from the peritoneal stores. 
Toxicity 
In most studies, the dose limiting toxicity for topotecan is
neutropenia, which is associated with thrombocytopenia in more
prolonged schedules (Abbruzzese et al, 1993; Kantarjian et al,
1993; Rowinsky et al, 1994; Van Warmerdam et al, 1995; Hochster
et al, 1995). In our study the dose-limiting toxicity was an acute
anaphylactoid reaction at the 30 mg/m2 level with only mild
myelosuppression and non-haematological toxicity even at this
dose. The severity of the toxic reaction precluded a further exten-
sion of the number of patients on this dose level. Furthermore, we
felt that an active dose has been reached to use in combined treat-
ment in a follow-up study, as the present level already constituted
2–3 times the cumulative dose level of 8–10 mg/m2 (Abruzzesse,
1993; van Warmerdam, 1995) in most IV studies. Further increase
of the dose was therefore not deemed clinically meaningful. In
sharp contrast with the only other study addressing the intraperi-
toneal administration of topotecan we arrived at a recommended
dosage of 20 mg/m2, instead of 3 mg/m2 when given as a contin-
uous 24-h IP infusion as recommended by the group of Howell
et al (Plaxe et al, 1998). This difference can only be explained by
the regimen, e.g. continuous infusion, but the exact cause for this
difference still remains obscure. It might be that less drug is
converted to the open-ring carboxy form, if the drug is given by
continuous infusion IP, but this has not been further elucidated by
pharmacokinetic studies. Although a lower dose will certainly
result in lower cost, little can be said about its efficacy in relation
to bolus IP infusion. The data of Hoskins et al were not yet avail-
able at the time this study was started, as this favoured a five times
daily schedule (Hoskins, 1998). 
The need for a more effective first-line regimen in advanced
ovarian cancer remains paramount. With the introduction of new
classes of chemotherapeutic agents that have demonstrated
activity in ovarian cancer, such as topotecan, the question of the
optimal first-line regimen remains open (Cannistra, 1999). The
renewed interest in multi-agent chemotherapy in ovarian cancer
has resulted in trials with combination of cytotoxic drugs given
simultaneously, sequentially or as alternating doublets (Herben
et al, 1999; Frasci et al, 1999; Cannistra, 1999). However, the limi-
tations of this approach have become apparent; even with growth
factor support achieving optimal dosages for the individual
agents. Therefore, the key to this problem may lie in IP therapy.
IP topotecan can be administered in relevant dosages without
major systemic effects. Subsequent trials with multi-agent
chemotherapy in ovarian cancer could then employ regimens
combining IP topotecan with IV paclitaxel and a platinum
compound. This might awaken a renewed interest in the role of IP
chemotherapy. 
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